Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise

Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers

Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers

Regeneron Pharmaceuticals topped third-quarter forecasts on Thursday, helped by a strong launch from its high dose of Eylea. REGN stock rose.

Investors Business Daily

Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) has an impressive revenue and earnings surprise history. So, as the company gears up to post its third-quarter report, is REGN the right pick? Read on.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Regeneron Bulls, Bears Clash: Will Biotech Get Eylea Mojo Back?

With Regeneron earnings due Nov. 2, the big debate is whether the company will get its mojo back in its core eye disease treatment business?

Investors Business Daily

Regeneron Pharmaceuticals Stock Earns 85 RS Rating

A Relative Strength Rating upgrade for Regeneron Pharmaceuticals shows improving technical performance.

Investors Business Daily

Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough'

Shares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals' high-dose Eylea following a delay this summer.

Investors Business Daily

IBD Screen Includes Meta, Tesla, Other Big Techs, But These Others Are In Buy Zones

This stock screener identified 26 stocks that mutual funds are adding. We highlight seven familiar names with several in buy zones.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks With 'A' POWR Ratings

3 Biotech Stocks With 'A' POWR Ratings

The biotech industry is poised for significant growth due to the rising orphan drug formulations and the adoption of emerging technologies. Therefore, fundamentally strong biotech stocks Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and United Therapeutics (UTHR) might be solid buys. These stocks are A (Strong Buy) rated in our proprietary…

Regeneron Sacrifices A Breakout As Competition Hammers At Its Biggest Moneymaker

Regeneron Sacrifices A Breakout As Competition Hammers At Its Biggest Moneymaker

The struggles continued for Regeneron's blockbuster eye disease treatment, Eylea, in the first quarter — leading REGN stock to dive Thursday.

Investors Business Daily

Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin

Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin

Regeneron Pharmaceuticals said sales of its linchpin Eylea drug have been negatively impacted by a short-term shift to rival drug Avastin.

Investors Business Daily

Dexcom Leads 5 Stocks Near Buy Points

Dexcom Leads 5 Stocks Near Buy Points

Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals.

Investors Business Daily

Regeneron Sinks Despite Massive Earnings Beat On A Notable Blockbuster Miss

Regeneron Sinks Despite Massive Earnings Beat On A Notable Blockbuster Miss

Regeneron Pharma topped third-quarter expectations Thursday, reporting less of a decline than expected. But REGN stock was down early.

Investors Business Daily

Regeneron Pharmaceuticals Unusual Options Activity

Regeneron Pharmaceuticals Unusual Options Activity

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange trades.

Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022

Regeneron Pharmaceuticals Whale Trades For October 03

Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022

Investors Business Daily

Regeneron Stock Soars On Pair Of Successful Trials

Studies "support aflibercept 8 mg as a potential new standard-of-care," Regeneron Pharmaceuticals said. Regeneron stock leapt in huge volume.

Get all your
news in one place.

100’s of premium titles.
One news app.

Regeneron Pharmaceuticals Whale Trades For September 06

Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

What Are Whales Doing With Regeneron Pharmaceuticals

A whale with a lot of money to spend has taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange trades.

Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2022

What Are Whales Doing With Regeneron Pharmaceuticals

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 52 strange trades.

This Foreboding Sign Looms Over Regeneron Pharmaceuticals's Chart

If history is any guide, there may be trouble ahead for shares of Regeneron Pharmaceuticals (NASDAQ:REGN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Here's How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 14.19% on an annualized basis producing an average annual return of 21.3%. Currently, Regeneron Pharmaceuticals has a market capitalization of $65.05 billion.

Regeneron Pharmaceuticals Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 34 strange trades.

People

Christopher Raymond

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

291,184 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play